Development of combinatorial drug against EGFR mutation in non-small cell lung cancer treatment
碩士 === 國立交通大學 === 分子醫學與生物工程研究所 === 102 === Oncologists are facing formidable challenges in overcoming cancers with either innate or acquired resistance to cancer therapies, especially for the cancers with EGFR mutation and activation. Therefore, the development of new drugs against drug resistance o...
Main Authors: | Huang, Yi-Ning, 黃薏寧 |
---|---|
Other Authors: | Ho, Shinn-Ying |
Format: | Others |
Language: | zh-TW |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/46220197275366201244 |
Similar Items
-
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
by: Bai H, et al.
Published: (2017-04-01) -
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
by: Yutaka Yamada, et al.
Published: (2021-09-01) -
Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
by: Mario Occhipinti, et al.
Published: (2021-05-01) -
The Detection Methods of EGFR Mutations in Non-small Cell Lung Cancer
by: Xinyu ZHANG, et al.
Published: (2011-03-01) -
EGFR mutation testing in non-small cell lung cancer (NSCLC)
by: Fouad Al Dayel
Published: (2012-12-01)